Guido Dalbagni, MD

Meet Urologic Cancer Surgeon Guido Dalbagni

WATCH VIDEO 02:00

Guido Dalbagni, MD

Urologic Surgeon

Clinical Expertise

Bladder Cancer; Upper Tract; Urologic Oncology; Kidney Cancer

New Patient Appointments

Scheduling a visit is easy. Click below or call us to get started.

Accepted Insurance Providers

Dr. Dalbagni accepts the following list of insurance providers. Select your insurance provider to see more details.

Contact and Location

Locations map

Find a Convenient Location

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.

About Me

Education

MBBCh, Cairo University Faculty of Medicine

Residencies

General Surgery - Cabrini Medical Center; Urology - New York University Medical Center

Fellowships

Urologic Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Urology

I am a urologic surgeon with expertise in the treatment of urologic tumors — which include bladder, urethral, and kidney cancers. I am currently heading clinical trials at Memorial Sloan Kettering to evaluate new therapies for the treatment of high-risk superficial bladder cancer in patients who are resistant to bacillus Calmette-Guérin (BCG) therapy, the standard treatment. I also have expertise in nerve-sparing radical cystectomy followed by bladder reconstruction.

I have written a number of articles, and I am on the editorial boards of and a reviewer for several peer-reviewed journals.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

Clinical Trials

Smiling doctors in the lab

Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Research and Publications

Dalbagni G, Russo P, Sheinfeld J, Mazumdar M, Tong W, Rabbani F, Donat MS, Herr HW, Sogani P, dePalma D, Bajorin D. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder.. J Clin Oncol. 2002; 20(15) :3193-8

Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer.. Urology 2002; 60(5) :824-825

Dalbagni G, Donat SM, Eschwege P, Herr HW, Zelefsky MJ. Results of high-dose brachytherapy (HDR-BRT), anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol 2001; 166 :1759-1761

Dalbagni G, Ren Z-P, Herr HW, Cordon-Cardo C, Reuter VE. Genetic alterations in TP53 in recurrent urothelial cancer: A longitudinal study. CI Cancer Res 2001; 7 :1797-2801

Dalbagni G, Genega E, Hashibe M, Zhang Z-F, Russo P, Herr HW, Reuter V. Cystectomy for Bladder Cancer: A Contemporary Series. J Urol 2001; 165 :1111-1116

Cozzi PJ, Bajorin DF, Tong W, Nguyen H, Scott J, Heston WDW, Dalbagni G. Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs. CI Cancer Res 1999; 5 :2629-2637

Dalbagni G, Reschtschaffen T, Herr HW. Is Transurethral Biopsy of the Bladder Necessary After 3 Months to Evaluate Response to BCG Therapy. J Urol 1999; 162 :708-709

Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Male Urethral Carcinoma: Analysis of Treatment Outcome. Urology 1999; 53 :1126-1132

Dalbagni G, Zhang Z-F, Lacombe L, Herr HW. Female Urethral Carcinoma: Analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol 1998; 82 :835-841

Publications on PubMed

Visit PubMed for a full listing of Dr. Dalbagni’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.